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Angiogenic gene therapy: pre-clinical studies and phase i clini- resulting from vascular occlusive diseases would require
cal data. Over the last three decades, significant progress has that the process of angiogenesis be augmented in the
been made in the management of patients with atherosclerotic hypoperfused myocardial and skeletal muscle tissues.coronary and peripheral vascular diseases using medical, surgi-
Attempts to augment local tissue perfusion in patientscal, and percutaneous therapies. Despite these advances, there
remains a significant population of patients who are not optimal who are not amenable to conventional surgical or percu-
candidates for surgical or percutaneous revascularization. These taneous revascularization have included:
patients continue to suffer from the debilitating symptoms of
their disease and remain at risk for myocardial infarction, limb
1. Use of angiogenic growth factors.loss, or death. It was this clinical need, coupled with the advances
in the understanding of angiogenesis, that has led to efforts to 2. Transmyocardial laser.
develop angiogenic therapies for patients with peripheral and 3. Low intensity electrical stimulation.
myocardial ischemia. In general, these conditions are character-
ized by local hypovascularity, and the approach to treatment
This review will focus on the first of these methods.is therefore focused on stimulating neovascularization.
METHODSAngiogenesis has been typically defined as formation
Angiogenic growth factors. The majority of the workof new blood vessel from pre-existing vessels by the
in therapeutic angiogenesis has been done using variousprocess of cellular outgrowth. It differs from vasculogen-
angiogenic growth factors. There are numerous angio-esis, which is typically considered an embryonic phenom-
genic growth factors that have been investigated as po-enon in which new blood vessels are formed from com-
mitted stem cells. While it is not clear what proportion tential agents for therapeutic angiogenesis: (Table 1).
of either of these processes comprises the response to Most clinical studies to date have focused on VEGF
tissue ischemia in humans, animal models suggest that and FGF.
both mechanisms contribute to new vessel growth, re- Vascular endothelial growth factor. VEGF is a se-
ferred to generically as neovascularization. Angiogenesis creted glycoprotein that has been identified in four ho-
can be both physiological and pathological, the former modemeric forms arising from alternative splicing of
being formation of new vessels after embryonic life in mRNA from a single gene. Each molecule contains 121,
processes such as wound healing and the female repro- 165, 189, or 206 amino acids and is capable of binding
ductive cycle. Examples of pathological processes involv- heparin or cell surface heparan sulfate proteoglycans.
ing angiogenesis include tumor growth, rheumatoid ar- All forms are mitogenic toward vascular endothelial cells
thritis, and diabetic retinopathy. and increase vascular permeability of blood vessels.
It was the work of Dr. Judah Folkman and his col- VEGF 165 is the predominant form.
leagues that identified the dependence of tumor growth VEGF can be administered either as a recombinant
on local angiogenesis and suggested that certain angio-
protein or as a gene encoding for this peptide.
genic growth factors were responsible for this process.
Therapy to limit or reverse tumor growth using inhibitors Gene transfer of VEGF
of angiogenic growth factors is now under investigation
A series of investigations in animals and humans haveand is showing promise [1].
demonstrated the feasibility of transferring naked plas-Conversely, the treatment of pathological ischemia
mid DNA encoding VEGF. Even though evidence of
transfection is noted in less than one percent of endothe-
lial cells, the secreted gene product has significant biolog- 2002 by the International Society of Nephrology
S-110
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Table 1. Angiogenic growth factors with potential from development of collaterals that are less than 180m
for therapeutic angiogenesis
in diameter, below the sensitivity of standard contrast
Angiogenic growth factor (Abbreviation) angiography.
Vascular endothelial growth factora (VEGF) One patient who received 2 mg dose of plasmid DNA
Basic fibroblast growth factor (bFGF/FGF2) did show direct angiographic evidence of new collateral
Acidic fibroblast growth factor (aFGF/FGF1)
vessels.Fibroblast growth factor 4 (FGF4)
Fibroblast growth factor 5 (FGF5) Intramuscular Gene therapy. Studies from our labora-
Angiopoietin 1a (Ang 1) tory have shown that transfection efficiency was in-
Angiopoietin 2a (Ang 2)
creased to 5% to 10% by intramuscular delivery of plas-Heparin-binding epidermal growth factor (HB-EGF)
Placental growth factora (PIGF) mid DNA into the ischemic tissue. Hence we studied
Scatter-factor hepatocyte growth factor (HGF) nine patients with critical limb ischemia, most of whom
Insulin-like growth factor (IGF)
have been advised to undergo amputation. Each patientPlatelet-derived growth factor (PDGF)
Transforming growth factor- (TGF-) was injected with 2 mgs of plasmid DNA at four sites
into the muscles of the ischemic limb. The same dosea Specific for endothelial cells
was repeated after four weeks.
The increase in VEGF level in the serum was docu-
mented by enzyme linked immunosorbant assay (ELISA).
ical effects. Several routes of administration have been The mean ankle-brachial index was increased from 0.33
studied. at baseline to 0.48 12 weeks later. The newly developed
Arterial VEGF gene transfer. In studies of arterial gene collaterals were seen both on MRA and contrast angiog-
transfer VEGF gene was delivered as naked DNA to raphy. Three patients with rest alone had complete relief
the internal iliac artery in rabbits with hind limb isch- of symptoms, while four of the seven patients with isch-
emia. The transfer was facilitated by applying solutions emic ulcers completely healed. To date, more than 75
of pure plasmid DNA to the hydrogel polymer coating patients with critical limb ischemia have been treated
of a standard angioplasty balloon. The balloon was in- with this form of therapy. Virtually all patients with rest
flated and DNA was transferred to the arterial wall. pain alone have been treated successfully and have been
Analysis of the transfected internal iliac artery using spared amputation. About half of the patients greater
reverse transcription PCR confirmed the presence of than 50 years of age have healed their ischemic ulcers
VEGF mRNA after gene transfer. Gene expression per- with this therapy. We have also observed that outcomes
sisted for 2–4 weeks after transient transfection with are better in younger patients [3].
naked DNA and evidence for new collateral vessels was A similar form of therapy was used in 11 patients
provided by serial angiography and by increased capil- with Buerger’s disease, nine of whom were successfully
lary density at necropsy. The ischemic limb also showed treated. These patients had resolution of nocturnal rest
improved hemodynamics in the form of increased calf pain and healing of ulcers. The ankle-brachial index in-
blood pressure ratio (CBR) and increased distal maxi- creased by greater than 0.1 and newly formed collateral
mum flow velocity in response to papaverine using a vessels were seen on MRA and serial contrast angiogra-
Doppler flow wire [2]. phy. Two of these patients needed below knee amputa-
Clinical studies. Eight patients with critical limb isch- tion because of advanced gangrene at the time of treat-
emia (pain at rest or non-healing ulcers), who were not ment initiation, although the level of amputation was
candidates for surgical revascularization, were enrolled. lowered in both patients [4].
The VEGF 165 gene was administered into the artery Treatment has been well tolerated. Adverse effects
in ascending doses in a Phase I study. The transfer site have been limited to transient ankle or calf edema, which
was examined by IVUS prior to delivery of the gene in responded well to diuretics. This has been attributed to
order to exclude evidence of atherosclerotic plaque or the increased vascular permeability due to VEGF.
intimal thickening. Three patients who had nocturnal Myocardial gene therapy. Based on the results of the
rest pain only received a 1 mg dose of VEGF 165. All Phase I trial in patients with peripheral vascular disease,
three patients became free of rest pain at three months. we also initiated a Phase I clinical study to assess the
MRA and contrast angiography demonstrated increased safety and efficacy of this therapy in patients with symp-
distal flow. Prior studies have suggested that the size of tomatic coronary artery disease who were not candidates
collateral vessels derived as a result of angiogenic gene for conventional forms of revascularization.
therapy will be below the limit of detection of contrast To date 82 patients, aged 53 to 71 years, have been
angiography, and contrast angiography failed to demon- enrolled in this study. All of these patients had class 3
strate new collateral vessels in these patients. DNA label- or 4 exertional angina refractory to maximum medical
ing studies in swine and canine models of myocardial therapy and had a reversible defect on SPECT-sestamibi
myocardial perfusion imaging and by electromechanicalischemia have established that increases in flow resulted
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mapping of the left ventricle. All patients had multi- statistically significant augmentation of angiographically
vessel coronary disease that was not amenable to percu- visible collateral vessels and histologically identifiable
taneous or surgical revascularization. The plasmid DNA capillaries. This also resulted in improved hemodynamics
encoding VEGF 165 or VEGF-2/VEGF-C was injected in the VEGF treated ischemic limb as compared with
directly into the ischemic myocardium by a mini left the control. Comparable results were obtained in an-
anterior thoracotomy or via a modified electomechanical other series of experiments in the same model, by using
mapping catheter. Three doses of VEGF 165 were used intramuscular rh VEGF once daily for 10 days.
(125g, 250g, and 500g) to treat a total of 30 patients, In similar pig experiments using arterial constriction to
and this was used as a sole therapy. Gene expression create area of myocardial ischemia, rh VEGF increased
was documented by the transient increase in serum levels myocardial blood flow. Banai et al reported similar re-
of VEGF monitored by ELISA. Patients tolerated this sults in the dog experiments using intracoronary VEGF.
therapy well and side effects were limited to unifocal Clinical studies. Henry et al reported the early results
PVCs. All patients had significant reduction in angina from VIVA trial, in which effect of intracoronary fol-
(S.l nitroglycerine use decreased from 59.3 to 2.9 tablets lowed by intravenous rh VEGF was evaluated in more
a week). This effect was usually seen within 21 days of than 140 patients. This was a double blind placebo con-
gene therapy. Objective evidence of reduced ischemia
trolled trial of patients with viable myocardium who were
was documented in 29/30 patients [5] both by SPECT-
not optimal candidates for percutaneous or surgical re-sestamibi scan as well as LV electromechanical mapping.
vascularization. The doses that were used were 17 andThe major advantage of this study is that it used this
50 ng/kg/min on days 0, 3, 6, and 9. Doses were limitedform of therapy as a sole intervention as opposed to
by hypotension that developed at higher doses in anmost of the other clinical studies that have used the
earlier dose-ranging study. The study showed that theregrowth factors in combination with CABG [6].
was significant decrease in angina class in both VEGFThis early experience leaves several issues unresolved.
groups as compared to placebo, however exercise tread-Optimizing the anatomic site, number, and dose of intra-
mill time and SPECT–sestambi scan did not show anymyocardial injection will require further investigation.
significant change. An interesting finding was that twoIncorporation of a placebo group and clinical testing of
patients in the placebo group were diagnosed with tu-alternative dosing regimens, including multiple treat-
mors after enrollment in this study. Angiographic dataments, will be addressed with a catheter-based system
is not yet available. So far in myocardial ischemia, thefor a reliable percutaneous myocardial gene delivery.
This is currently in the early phases of investigation with intramuscular rh VEGF has been used in two patients
22 patients enrolled in a randomized, placebo controlled without any complications. The follow up results are
study of VEGF-2/VEGF-C administered using the Bio- awaited [9].
sense mapping catheter that has been modified to allow Fibroblast growth factor (FGF). FGF is actually a fam-
injection of plasmid DNA solution into the endocardial ily of nine factors, namely basic FGF, acidic FGF, and
surface of the beating heart via a femoral artery ap- FGF 3–9.
proach. This device was also used in the Phase I study Basic FGF is an 18 kD single chain peptide of 154
of VEGF 165 and provided additional objective evidence amino acids with both angiogenic and mitogenic poten-
of ischemia reduction that correlated with the perfusion tial. Acidic FGF is a 16 kD cationic polypeptide chain
scan data [7]. made up of 140 amino acids and possesses a 55% se-
The use of adenoviral vector expressing VEGF 121 quence homology with bFGF. However, the one that is
was reported to significantly improve myocardial perfu- predominantly found in myocardium is bFGF. FGF’s
sion and function in a swine model of myocardial isch-
are non-secreted growth factors lacking a signal peptide
emia. This group documented myocardial perfusion and
sequence, that is, it remains sequestrated in cells thatfunction by SPECT-sestamibi and by echocardiography
produce them. Extracellular release of FGF is caused byduring rest and stress. Currently this form of therapy is
cell death or damage. These growth factors have strongbeing tested in humans. So far, 7 patients have received
affinity for heparin and heparin like substances. A seriesdirect myocardial injection into the region of ischemic
of animal experiments have demonstrated that FGF im-myocardium. No adverse effect of this therapy has been
proves myocardial perfusion and function in both acutenoted to date [8].
and chronic ischemia. This improvement was as a result
Recombinant human VEGF (rh VEGF) of angiographically documented and histologically iden-
tifiable sprouting of capillary network from the originalThe evidence that VEGF stimulates angiogenesis was
coronary vessels. After a reasonable exclusion of thefirst developed in experiments performed in a rabbit model
tumor proliferating action of these growth factors, clini-of unilateral hind limb ischemia. Our group showed that
doses of 500 to 1000 micrograms of rh VEGF produced a cal studies have been started.
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Clinical studies poietin 1, human hepatocyte growth factor, acidic FGF.
However, there are no clinical trials reported so far.The three major ongoing clinical studies are as follows.
(a) Intracoronary recombinant FGF-2. This was de-
Combination of growth factorslivered as a single 20 minute infusion divided between
Several studies both in vitro and in vivo have demon-two major sources of coronary blood supply in patients
strated that various combinations of these growth factorswith non revascularizable coronary artery disease. In this
have a synergistic effect on the process of angiogenesis.open labeled, dose escalation multi-center trial there was
Asahara et al. from our lab demonstrated a synergistica statistically significant decrease in angina class (2.6 
effect of rhFGF and rh VEGF in a rabbit model of0.7 to 1.2  0.8), increase in exercise tolerance (8.5 
unilateral hind limb ischemia. There was a statistically2.6 min to 10.0  2.5 min), and improved regional LV
significant increase in calf blood pressure ratio, luminalfunction and perfusion by MRI. However, there was no
diameter of the stem collaterals, number of opacifiedimprovement noted in the SPECT sestamibi scan. The
collaterals, stem artery diameter, and capillary densityadverse effects that were noted include hypotension and
in the VEGF bFGF group as compared with VEGF ortransient renal dysfunction. There were three deaths and
bFGF alone. The fundamental basis for the synergisticfour myocardial infarctions reported so far on the follow-
up [10]. effect of VEGF and bFGF remains to be elucidated. Fol-
(b) Perivascular bFGF. In patients undergoing CABG lowing are a few postulated hypothesis: VEGF is endo-
with viable and ischemic but non-graftable myocardial thelial cell specific while bFGF acts on a variety of other
territory, bFGF was implanted in the subepicardial fat cell types including smooth muscle cells. It might be the
along the distribution of ungraftable vessels. In this ran- combination of EC and SMC stimulation that results in
domized, double-blinded, placebo-controlled study, 10 enhanced angiogenesis. VEGF and bFGF act in different
heparin alginate microcapsules containing 10 or 100 mi- receptor systems. It may be that simultaneous stimula-
crograms of bFGF or placebo were used. It was reported tion of both the systems will be able to produce amplifi-
to be well tolerated with no serious adverse effects. How- cation of the endothelial cell response. Park et al have
ever, in this group two patients died intraoperatively (1 recently proposed another possible mechanism. They
control and 1100 gm bFGF group), and one patient demonstrated that PIGF potentiates VEGF-induced EC
had a periop. Native MI (10 gm bFGF group). The growth in vitro and Evan’s blue dye extravasation in vivo.
preliminary data suggested improvement in angina, myo- While PIGF binds with Flt-1, it doesn’t bind KDR recep-
cardial perfusion and regional function in the 100 gm tors, which account for most of the bioactivity of VEGF.
bFGF group (Laham, Simons, et al 1998 #2256). Compa- These authors suggest that interaction of PIGF and Flt-1
rable results were reported by the same group in another leads to release of VEGF from Flt-1 and increases its
study of eight patients using similar technique of admin- availability to more relevant KDR receptors. Whether
istration [11]. a similar mechanism exists for VEGF and bFGF remains
(c) Intramyocardial rhFGF. This was used in conjunc- to be investigated.
tion with CABG in patients with additional peripheral
stenosis of the IMA grafted LAD. In this randomized, Safety concerns
double-blinded, placebo-controlled study, 40 patients
Angiogenesis and risk of cancer. Many angiogenic fac-were enrolled (20 in FGF group and 20 in placebo group).
tors are known to be involved in tumor growth secondaryA 12 week follow up angiography revealed that all pa-
to enhancing angiogenesis, which is vital for growth oftients in FGF group had an increased contrast uptake
most tumors, particularly solid tumors. Hence, in theory,(sprouting capillary network) at the site of growth factor
angiogenic growth factors may lead to development ofinjection. This was noted to revascularize the vessel be-
tumors and they may be too small to be recognized.yond the site of peripheral stenosis. No such contrast
Even so, there is no evidence so far that this can occur.uptake was noted in the placebo group that was injected
It was very interesting to note in VIVA Trial that therewith physiological saline. These findings were analyzed
was a greater incidence of tumors in placebo group thanand supported by quantitative gray value analysis of con-
in the VEGF group. This exemplifies the fact that thetrast medium accumulation [12].
age group receiving such therapy will develop some unre-These early results with FGF, although encouraging,
lated tumors. Nevertheless, we must be vigilant aboutare mostly seen in patients who are surgically revascu-
the possibility of cancer in patients treated with theselarized at the same time, which makes it difficult to ana-
angiogenic growth factors.lyze end points like decrease in angina or improvement
Risks of retinopathy. It is theoretically possible thatin myocardial perfusion scans.
overgrowth of vessels in the retina may either induce
Other growth factors diabetic retinopathy or worsen the existing pathology
leading to loss of vision. To date, this adverse effectSome of the other growth factors that have shown
beneficial results in animal experiments include angio- of therapeutic angiogenesis has not been observed. As
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